{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:09:34Z","timestamp":1778490574358,"version":"3.51.4"},"reference-count":72,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Coronavirus disease 2019 (COVID-19) was reported as a global pandemic in March 2020 after invading many countries and leaving behind tens of thousands of infected patients in a brief time span. Approval of a few vaccines has been obtained and their efficacy of varying degrees established. Still, there is no effective pharmaceutical agent for the treatment of COVID-19 though several drugs are undergoing clinical trials. Recent studies have shown that dexamethasone, a corticosteroid, can reduce the rate of COVID-19-related mortality in the intensive care unit by 35 % for patients who are on mechanical ventilation. Although variable efficacy of other combination therapies has been reported for treating COVID-19 associated with acute respiratory distress syndrome (ARDS), dexamethasone is an extensively used drug in many treatment regimens against COVID-19. The current review aims to explore the role of dexamethasone as an efficient combination treatment for COVID-19.<\/jats:p>","DOI":"10.2478\/acph-2022-0030","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T12:05:33Z","timestamp":1649851533000},"page":"345-358","source":"Crossref","is-referenced-by-count":5,"title":["The effectiveness of dexamethasone as a combination therapy for COVID-19"],"prefix":"10.2478","volume":"72","author":[{"given":"Nader","family":"Namazi","sequence":"first","affiliation":[{"name":"Pharmaceutics and Pharmaceutical Technology Department College of Pharmacy , Taibah University Al Madinah Al Munawarah Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"key":"2026051108194149873_j_acph-2022-0030_ref_001","doi-asserted-by":"crossref","unstructured":"1. Y. Shang, C. Pan, X. Yang, M. Zhong, X. Shang, Z. Wu, Z. Yu, W. Zhang, Q. Zhong and X. Zheng, L. Sang, L. Jiang, J. Zhang, W. Xiong, J. Liu and D. Chen, Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China, Ann. Intensive Care 10(1) (2020) Article ID 73 (24 pages); https:\/\/doi.org\/10.1186\/s13613-020-00689-110.1186\/s13613-020-00689-1727565732506258","DOI":"10.1186\/s13613-020-00689-1"},{"key":"2026051108194149873_j_acph-2022-0030_ref_002","doi-asserted-by":"crossref","unstructured":"2. P. Wang, M. S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P. D. Kwong, B. S. Graham, J. R. Mascola, J. Y. Chang, M. T. Yin, M. Sobieszczyk, C. A. Kyratsous, L. Shapiro, Z. Sheng, Y. Huang and D. D. Ho, Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1.7, Nature 593 (2021) 130\u2013135; https:\/\/doi.org\/10.1038\/s41586-021-03398-210.1038\/s41586-021-03398-233684923","DOI":"10.1038\/s41586-021-03398-2"},{"key":"2026051108194149873_j_acph-2022-0030_ref_003","doi-asserted-by":"crossref","unstructured":"3. S. Su, G. Wong, W. Shi, J. Liu, A. K. Lai, J. Zhou, W. Liu, Y. Bi and G .F. Gao, Epidemiology, genetic recombination, and pathogenesis of coronaviruses, Trends Microbiol. 24(6) (2016) 490\u2013502; https:\/\/doi.org\/10.1016\/j.tim.2016.03.00310.1016\/j.tim.2016.03.003712551127012512","DOI":"10.1016\/j.tim.2016.03.003"},{"key":"2026051108194149873_j_acph-2022-0030_ref_004","doi-asserted-by":"crossref","unstructured":"4. K. Liu, Y.-Y. Fang, Y. Deng, W. Liu, M.-F. Wang, J.-P. Ma, W. Xiao, Y.-N. Wang, M.-H. Zhong, C.-H. Li, G.-C. Li and H.-G. Liu, Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province, Chin. Med. J. 133(9) (2020) 1025\u20131031; https:\/\/doi.org\/10.1097\/CM9.000000000000074410.1097\/CM9.0000000000000744714727732044814","DOI":"10.1097\/CM9.0000000000000744"},{"key":"2026051108194149873_j_acph-2022-0030_ref_005","unstructured":"5. C. W. K. Lam, M. H. M. Chan and C. K. Wong, Severe acute respiratory syndrome: Clinical and laboratory manifestations, Clin. Biochem. Rev. 25(2) (2004) 121\u2013132."},{"key":"2026051108194149873_j_acph-2022-0030_ref_006","doi-asserted-by":"crossref","unstructured":"6. S. Lu, Q. Zhou, L. Huang, Q. Shi, S. Zhao, Z. Wang, W. Li, Y. Tang, Y. Ma, X. Luo, T. Fukuoka, H. S. Ahn, M. S. Lee, Z. Luo, E. Liu, Y. Chen, C. Zhou and D. Peng (on behalf of COVID-19 Evidence and Recommendations Working Group), Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis, Ann. Transl. Med. 8(10) (2020) Article ID 627 (21 pages); https:\/\/doi.org\/10.21037\/atm-20-330710.21037\/atm-20-3307729062832566564","DOI":"10.21037\/atm-20-3307"},{"key":"2026051108194149873_j_acph-2022-0030_ref_007","doi-asserted-by":"crossref","unstructured":"7. M. Merad and J. C. Martin, Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages, Nat. Rev. Immunol. 20 (2020) 355\u2013362; https:\/\/doi.org\/10.1038\/s41577-020-0331-410.1038\/s41577-020-0331-4720139532376901","DOI":"10.1038\/s41577-020-0331-4"},{"key":"2026051108194149873_j_acph-2022-0030_ref_008","doi-asserted-by":"crossref","unstructured":"8. M. Z. Tay, C. M. Poh, L. R\u00e9nia, P. A. MacAry and L. P. Ng, The trinity of COVID-19: immunity, inflamma tion and intervention, Nat. Rev. Immunol. 20 (2020) 363\u2013374; https:\/\/doi.org\/10.1038\/s41577-020-0311-810.1038\/s41577-020-0311-8718767232346093","DOI":"10.1038\/s41577-020-0311-8"},{"key":"2026051108194149873_j_acph-2022-0030_ref_009","doi-asserted-by":"crossref","unstructured":"9. A. G. Harriso, T. Lin and P. Wang, Mechanisms of SARS-CoV-2 transmission and pathogenesis, Trends Immunol. 41(12) (2020) 1100\u20131115; http:\/\/doi.org\/10.1016\/j.it.2020.10.00410.1016\/j.it.2020.10.004755677933132005","DOI":"10.1016\/j.it.2020.10.004"},{"key":"2026051108194149873_j_acph-2022-0030_ref_010","doi-asserted-by":"crossref","unstructured":"10. X. Sun, T. Wang, D. Cai, Z. Hu, J. Chen, H. Liao, L. Zhi, H. Wei, Z. Zhang, Y. Qiu and J. Wang, Cytokine storm intervention in the early stages of COVID-19 pneumonia, Cytokine Growth Factor Rev. 53 (2020) 38\u201342; https:\/\/doi.org\/10.1016\/j.cytogfr.2020.04.00210.1016\/j.cytogfr.2020.04.002718252732360420","DOI":"10.1016\/j.cytogfr.2020.04.002"},{"key":"2026051108194149873_j_acph-2022-0030_ref_011","doi-asserted-by":"crossref","unstructured":"11. Q. Ruan, K. Yang, W. Wang, L. Jiang and J. Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med. 46 (2020) 846\u2013848; https:\/\/doi.org\/10.1007\/s00134-020-05991-x10.1007\/s00134-020-05991-x708011632125452","DOI":"10.1007\/s00134-020-05991-x"},{"key":"2026051108194149873_j_acph-2022-0030_ref_012","doi-asserted-by":"crossref","unstructured":"12. K. Yuki, M. Fujiogi and S. Koutsogiannaki, COVID-19 pathophysiology: A review, Clin. Immunol. 215 (2020) Article ID 108427; https:\/\/doi.org\/10.1016\/j.clim.2020.10842710.1016\/j.clim.2020.108427","DOI":"10.1016\/j.clim.2020.108427"},{"key":"2026051108194149873_j_acph-2022-0030_ref_013","doi-asserted-by":"crossref","unstructured":"13. X. Fang, Q. Mei, T. Yang, L. Li, Y. Wang, F. Tong, S. Geng and A. Pan, Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19, J. Infect. 81(1) (2020) 147\u2013178; https:\/\/doi.10.1016\/j.jinf.2020.03.039","DOI":"10.1016\/j.jinf.2020.03.039"},{"key":"2026051108194149873_j_acph-2022-0030_ref_014","unstructured":"14. V. Selvaraj, K. Dapaah-Afriyie, A. Finn and T. P. Flanigan, Short-term dexamethasone in Sars-CoV-2 patients, RI Med. J. 103 (2020) 39\u201343; https:\/\/doi.org\/10.1101\/2020.06.19.2010917310.1101\/2020.06.19.20109173"},{"key":"2026051108194149873_j_acph-2022-0030_ref_015","doi-asserted-by":"crossref","unstructured":"15. P. Sinha, A. Mostaghim, C. G. Bielick, A. McLaughlin, D. H. Hamer, L. M. Wetzler, N. Bhadelia, M. A. Fagan, B. P. Linas, S. A. Assoumou, M. H. Ieong, N. H. Lin, E. R, Cooper, K. D. Brade, L. F. White, T. F. Barlam and M. Sagar, Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge, Int. J. Infect. Dis. 99 (2020) 28\u201333; https:\/\/doi.org\/10.1016\/j.ijid.2020.07.02310.1016\/j.ijid.2020.07.023","DOI":"10.1016\/j.ijid.2020.07.023"},{"key":"2026051108194149873_j_acph-2022-0030_ref_016","doi-asserted-by":"crossref","unstructured":"16. D. Wu, Q. Rao and W. Zhang, The natural course of COVID-19 patients without clinical intervention, J. Med. Virol. 93 (2021) 5527\u20135537; https:\/\/doi.org\/10.1002\/jmv.2708710.1002\/jmv.27087","DOI":"10.1002\/jmv.27087"},{"key":"2026051108194149873_j_acph-2022-0030_ref_017","doi-asserted-by":"crossref","unstructured":"17. C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang and B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395(10223) (2020) 497\u2013506; https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-510.1016\/S0140-6736(20)30183-5","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"2026051108194149873_j_acph-2022-0030_ref_018","doi-asserted-by":"crossref","unstructured":"18. J. Phua, L. Weng, L. Ling, M. Egi, C. M. Lim, J. V. Divatia, B. R. Shrestha, Y. M. Arabi, J. Ng, C. D. Gomersall, M. Nishimura, Y. Koh and B. Du, Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations, Lancet Respir. Med. 8 (2020) 506\u2013517; https:\/\/doi.org\/10.1016\/S2213-2600(20)30161-210.1016\/S2213-2600(20)30161-2","DOI":"10.1016\/S2213-2600(20)30161-2"},{"key":"2026051108194149873_j_acph-2022-0030_ref_019","doi-asserted-by":"crossref","unstructured":"19. Z. Xiang, J. Liu, D. Shi, W. Chen, J. Li, R. Yan, Y. Bi, W. Hu, Z. Zhu, Y. Yu and Z. Yang, Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels, Int. J. Biol. Sci. 16(13) (2020) 2382\u20132391; https:\/\/doi.org\/10.7150\/ijbs.4765210.7150\/ijbs.47652","DOI":"10.7150\/ijbs.47652"},{"key":"2026051108194149873_j_acph-2022-0030_ref_020","doi-asserted-by":"crossref","unstructured":"20. M. Lester, A. Sahin and A. Pasyar, The use of dexamethasone in the treatment of COVID-19, Ann. Med. Surg. (London) 56 (2020) 218\u2013219; https:\/\/doi.org\/10.1016\/j.amsu.2020.07.00410.1016\/j.amsu.2020.07.004","DOI":"10.1016\/j.amsu.2020.07.004"},{"key":"2026051108194149873_j_acph-2022-0030_ref_021","doi-asserted-by":"crossref","unstructured":"21. P. Horby, W. S. Lim, J. R. Emberson, M. Mafham, J. L. Bell, L. Linsell, N. Staplin, C. Brightling, A. Ustianowski, E. Elmahi, B. Prudon, C. Green, T. Felton, D. Chadwick, K. Rege, C. Fegan, L. C. Chappell, S. N. Faust, T. Jaki, K. Jeffery, A. Montgomery, K. Rowan, E. Juszczak, J. K. Baillie, R. Haynes, M. J. Landray (The RECOVERY Collaborative Group), Dexamethasone in hospitalized patients with Covid-19 \u2013 preliminary report, N. Engl. J. Med. 384(8) (2021) 693\u2013704; https:\/\/doi.org\/10.1056\/NEJMoa202143610.1056\/NEJMoa2021436","DOI":"10.1056\/NEJMoa2021436"},{"key":"2026051108194149873_j_acph-2022-0030_ref_022","doi-asserted-by":"crossref","unstructured":"22. C. D. Russell, J. E. Millar and J. K. Baillie, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet 395 (2020) 473\u2013475; https:\/\/doi.org\/10.1016\/S0140-6736(20)30317-210.1016\/S0140-6736(20)30317-2","DOI":"10.1016\/S0140-6736(20)30317-2"},{"key":"2026051108194149873_j_acph-2022-0030_ref_023","doi-asserted-by":"crossref","unstructured":"23. J. Villar, C. Ferrando, D. Mart\u00ednez, A. Ambr\u00f3s, T. Mu\u00f1oz, J. A. Soler, G. Aguilar, F. Alba, E. Gonz\u00e1lez-Higueras, L. A. Conesa, C. Mart\u00edn-Rodr\u00edguez, F. J. D\u00edaz-Dom\u00ednguez, P. Serna-Grande, R. Rivas, J. Ferreres, Javier Belda, L. Capilla, A. Tallet, J. M. A\u00f1\u00f3n, R. L. Fern\u00e1ndez and J. M. Gonz\u00e1lez-Mart\u00edn, Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial, Lancet Respir. Med. 8 (2020) 267\u2013276; https:\/\/doi.org\/10.1016\/S2213-2600(19)30417-510.1016\/S2213-2600(19)30417-5","DOI":"10.1016\/S2213-2600(19)30417-5"},{"key":"2026051108194149873_j_acph-2022-0030_ref_024","doi-asserted-by":"crossref","unstructured":"24. A. A. Ordonez, M. Maiga, S. Gupta, E. A. Weinstein, W. R. Bishai and S. K. Jain, Novel adjunctive therapies for the treatment of tuberculosis, Curr. Mol. Med. 14(3) (2014) 385\u2013395; https:\/\/doi.org\/10.2174\/156652401366613111811243110.2174\/1566524013666131118112431448477424236454","DOI":"10.2174\/1566524013666131118112431"},{"key":"2026051108194149873_j_acph-2022-0030_ref_025","doi-asserted-by":"crossref","unstructured":"25. A. Grzanka, M. Misio\u0142ek, W. Golusi\u0144ski and J. Jarz\u0105b, Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposis, Eur. Arch. Oto-Rhino-Laryngol. 268 (2011) 247\u2013253; https:\/\/doi.org\/10.1007\/s00405-010-1330-z10.1007\/s00405-010-1330-z302118620628753","DOI":"10.1007\/s00405-010-1330-z"},{"key":"2026051108194149873_j_acph-2022-0030_ref_026","unstructured":"26. I. B. Mitre-Aguilar, A. J. Cabrera-Quintero and A. Zentella-Dehesa, Genomic and non-genomic effects of glucocorticoids: implications for breast cancer, Int. J. Clin. Exp. Pathol. 8(1) (2015) 1\u201310."},{"key":"2026051108194149873_j_acph-2022-0030_ref_027","doi-asserted-by":"crossref","unstructured":"27. M. Karn, S. Yonghang and S. Ghimire, Corticosteroids in COVID-19: We should be mindful of their acute toxicities, J. Clin. Pharmacol. 61(10) (2021) 1301\u20131302; https:\/\/doi.org\/10.1002\/jcph.193610.1002\/jcph.1936842674534196415","DOI":"10.1002\/jcph.1936"},{"key":"2026051108194149873_j_acph-2022-0030_ref_028","doi-asserted-by":"crossref","unstructured":"28. S. S. Hasan, T. Capstick, R. Ahmed, C. S. Kow, F. Mazhar, H. A. Merchant and S. R. Zaidi, Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a syste matic review and meta-analysis, Expert Rev. Respir. Med. 14(11) (2020) 1149\u20131163; https:\/\/doi.org\/10.1080\/17476348.2020.180436510.1080\/17476348.2020.1804365754496832734777","DOI":"10.1080\/17476348.2020.1804365"},{"key":"2026051108194149873_j_acph-2022-0030_ref_029","doi-asserted-by":"crossref","unstructured":"29. F. Chen, L. Hao, S. Zhu, X. Yang, W. Shi, K. Zheng, T. Wang and H. Chen, Potential adverse effects of dexamethasone therapy on COVID-19 patients: Review and recommendations, Infect. Dis. Ther. 10(4) (2021) 1907\u20131931; https:\/\/doi.org\/10.1007\/s40121-021-00500-z10.1007\/s40121-021-00500-z829804434296386","DOI":"10.1007\/s40121-021-00500-z"},{"key":"2026051108194149873_j_acph-2022-0030_ref_030","doi-asserted-by":"crossref","unstructured":"30. R. Zhao, H. Wang, X. Wang and F. Feng, Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis, Osteoporos. Int. 28 (2017) 1027\u20131034; https:\/\/doi.org.10.1007\/s00198-016-3824-z","DOI":"10.1007\/s00198-016-3824-z"},{"key":"2026051108194149873_j_acph-2022-0030_ref_031","doi-asserted-by":"crossref","unstructured":"31. X. Li and X. Ma, Acute respiratory failure in COVID-19: is it \u201ctypical\u201d ARDS? Crit. Care 24 (2020) Article ID 198 (5 pages); https:\/\/doi.org\/10.1186\/s13054-020-02911-910.1186\/s13054-020-02911-9720279232375845","DOI":"10.1186\/s13054-020-02911-9"},{"key":"2026051108194149873_j_acph-2022-0030_ref_032","unstructured":"32. M. Yasir, A. Goyal, P. Bansal and S. Sonthalia, Corticosteroid Adverse Effects, in StatPearls [Internet], StatPearls Publishing, Treasure Island (FL, USA) 2022."},{"key":"2026051108194149873_j_acph-2022-0030_ref_033","doi-asserted-by":"crossref","unstructured":"33. L. Kornel, A. V. Prancan, N. Kanamarlapudi, J. Hynes and E. Kuzianik, Study on the mechanisms of glucocorticoid-induced hypertension: glucocorticoids increase transmembrane Ca2+ influx in vascular smooth muscle in vivo, Endocr. Res. 21(1\u20132) (1995) 203\u2013210; https:\/\/doi.org\/10.3109\/0743580950903043610.3109\/074358095090304367588382","DOI":"10.3109\/07435809509030436"},{"key":"2026051108194149873_j_acph-2022-0030_ref_034","doi-asserted-by":"crossref","unstructured":"34. K. Smets and P. Vanhaesebrouck, Dexamethasone associated systemic hypertension in low birth weight babies with chronic lung disease, Eur. J. Pediatr. 155 (1996) 573\u2013575.10.1007\/BF019579078831080","DOI":"10.1007\/BF01957907"},{"key":"2026051108194149873_j_acph-2022-0030_ref_035","doi-asserted-by":"crossref","unstructured":"35. L. Berbegal, F. J. DeLeon and J. F. Silvestre, Hypersensitivity reactions to corticosteroids, Actas Dermo-Sifiliogr. (Engl.) 107(2) (2016) 107\u2013115; https:\/\/doi.org\/10.1016\/j.adengl.2016.01.00310.1016\/j.adengl.2016.01.003","DOI":"10.1016\/j.adengl.2016.01.003"},{"key":"2026051108194149873_j_acph-2022-0030_ref_036","doi-asserted-by":"crossref","unstructured":"36. J. E. Henriksen, F. Alford, G. M. Ward and H. Beck-Nielsen, Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients, Diabetologia 40 (1997) 1439\u20131448; https:\/\/doi.org\/10.1007\/s00125005084710.1007\/s001250050847","DOI":"10.1007\/s001250050847"},{"key":"2026051108194149873_j_acph-2022-0030_ref_037","doi-asserted-by":"crossref","unstructured":"37. G. F. Keenan, Management of complications of glucocorticoid therapy, Clin. Chest Med. 18(3) (1997) 507\u2013520; https:\/\/doi.org\/10.1016\/S0272-5231(05)70398-110.1016\/S0272-5231(05)70398-1","DOI":"10.1016\/S0272-5231(05)70398-1"},{"key":"2026051108194149873_j_acph-2022-0030_ref_038","doi-asserted-by":"crossref","unstructured":"38. H. O. Conn and T. Poynard, Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy, J. Intern. Med. 236(6) (1994) 619\u2013632; https:\/\/doi.org\/10.1111\/j.1365-2796.1994.tb00855.x10.1111\/j.1365-2796.1994.tb00855.x7989897","DOI":"10.1111\/j.1365-2796.1994.tb00855.x"},{"key":"2026051108194149873_j_acph-2022-0030_ref_039","doi-asserted-by":"crossref","unstructured":"39. N. K. Lee, S. Kim, S. B. Hong, S. J. Lee, T. U. Kim, H. Ryu, J. W. Lee, J. Y. Kim and H. B. Suh, CT diagnosis of non-traumatic gastrointestinal perforation: an emphasis on the causes, Jpn. J. Radiol. 38 (2020) 101\u2013111; https:\/\/doi.org\/10.1007\/s11604-019-00910-710.1007\/s11604-019-00910-731848888","DOI":"10.1007\/s11604-019-00910-7"},{"key":"2026051108194149873_j_acph-2022-0030_ref_040","doi-asserted-by":"crossref","unstructured":"40. P. C. Ng, K. G. Brownlee and P. R. Dear, Gastroduodenal perforation in preterm babies treated with dexamethasone for bronchopulmonary dysplasia, Arch. Dis. Child. 66 (1991) 1164\u20131166; https:\/\/doi.org\/10.1136\/adc.66.10_Spec_No.116410.1136\/adc.66.10_Spec_No.116415902771750771","DOI":"10.1136\/adc.66.10_Spec_No.1164"},{"key":"2026051108194149873_j_acph-2022-0030_ref_041","doi-asserted-by":"crossref","unstructured":"41. R. Alexanian, M. A. Dimopoulos, K. Delasalle and B. Barlogie, Primary dexamethasone treatment of multiple myeloma, Blood 80(4) (1992) 887\u2013890; https:\/\/doi.org\/10.1182\/blood.V80.4.887.88710.1182\/blood.V80.4.887.887","DOI":"10.1182\/blood.V80.4.887.bloodjournal804887"},{"key":"2026051108194149873_j_acph-2022-0030_ref_042","doi-asserted-by":"crossref","unstructured":"42. M. A. Kerachian, C. S\u00e9guin and E. J. Harvey, Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action, J. Steroid Biochem. Mol. Biol. 114(3) (2009) 121\u2013128; https:\/\/doi.org\/10.1016\/j.jsbmb.2009.02.00710.1016\/j.jsbmb.2009.02.007712623519429441","DOI":"10.1016\/j.jsbmb.2009.02.007"},{"key":"2026051108194149873_j_acph-2022-0030_ref_043","doi-asserted-by":"crossref","unstructured":"43. X. Wu, C. Geng, W. Sun and M. Tan, Incidence and risk factors of osteonecrosis of femoral head in multiple myeloma patients undergoing dexamethasone-based regimens, BioMed Res. Int. 2020 (2020) Article ID 7126982 (7 pages); https:\/\/doi.org\/10.1155\/2020\/712698210.1155\/2020\/7126982724641132509867","DOI":"10.1155\/2020\/7126982"},{"key":"#cr-split#-2026051108194149873_j_acph-2022-0030_ref_044.1","unstructured":"44. N. K. Rahayu and A. Emily, Clinical profile of steroid-induced glaucoma in Bali Mandara Eye Hospital year 2019, Intisari Sains Medis 12(1) (2021) 6-8"},{"key":"#cr-split#-2026051108194149873_j_acph-2022-0030_ref_044.2","unstructured":"44. N. K. Rahayu and A. Emily, Clinical profile of steroid-induced glaucoma in Bali Mandara Eye Hospital year 2019, Intisari Sains Medis 12"},{"key":"#cr-split#-2026051108194149873_j_acph-2022-0030_ref_044.3","unstructured":"(1) (2021) 6-8; https:\/\/doi.org\/10.15562\/ism.v12i1.872"},{"key":"2026051108194149873_j_acph-2022-0030_ref_045","doi-asserted-by":"crossref","unstructured":"45. G. S. Zode, A. B. Sharma, X. Lin, C. C. Searby, K. Bugge, G. H. Kim, A. F. Clark and V. C. Sheffield, Ocular-specific ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma, J. Clin. Invest. 124 (2014) 1956\u20131965; https:\/\/doi.org\/10.1172\/JCI6977410.1172\/JCI69774400153224691439","DOI":"10.1172\/JCI69774"},{"key":"2026051108194149873_j_acph-2022-0030_ref_046","unstructured":"46. M. D. Kamitsuka, M. A. Williams, D. A. Nyberg, K. A. Fox, D. L. Lee and D. Hickok, Renal calcification: a complication of dexamethasone therapy in preterm infants with bronchopulmonary dysplasia, J. Perinatol. 15 (1995) 359\u2013363."},{"key":"2026051108194149873_j_acph-2022-0030_ref_047","doi-asserted-by":"crossref","unstructured":"47. D. J. Cranefield, D. E. Odd, J. E. Harding and R. L. Teele, High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone, Pediatr. Radiol. 34 (2004) 138\u2013142; https:\/\/doi.org\/10.1007\/s00247-003-1090-710.1007\/s00247-003-1090-714624322","DOI":"10.1007\/s00247-003-1090-7"},{"key":"2026051108194149873_j_acph-2022-0030_ref_048","doi-asserted-by":"crossref","unstructured":"48. K. Gendo, S. D. Sullivan, P. Lozano, J. A. Finkelstein, A. Fuhlbrigge and K. B. Weiss, Resource costs for asthma-related care among pediatric patients in managed care, Ann. Allergy Asthma Immunol. 91(3) (2003) 251\u2013257; https:\/\/doi.org\/10.1016\/S1081-1206(10)63526-010.1016\/S1081-1206(10)63526-0","DOI":"10.1016\/S1081-1206(10)63526-0"},{"key":"2026051108194149873_j_acph-2022-0030_ref_049","doi-asserted-by":"crossref","unstructured":"49. D. C. Perantie and E. S. Brown, Corticosteroids, immune suppression, and psychosis, Curr. Psychiatry Rep. 4 (2002) 171\u2013176; https:\/\/doi.org\/10.1007\/s11920-002-0023-810.1007\/s11920-002-0023-812003678","DOI":"10.1007\/s11920-002-0023-8"},{"key":"2026051108194149873_j_acph-2022-0030_ref_050","doi-asserted-by":"crossref","unstructured":"50. R. Hajjo, D. A. Sabbah and S. K. Bardaweel, Chemocentric informatics analysis: Dexamethasone versus combination therapy for COVID-19, ACS Omega 5(46) (2020) 29765\u201329779; https:\/\/doi.org\/10.1021\/acsomega.0c0359710.1021\/acsomega.0c03597768966233251412","DOI":"10.1021\/acsomega.0c03597"},{"key":"2026051108194149873_j_acph-2022-0030_ref_051","doi-asserted-by":"crossref","unstructured":"51. T. Izumo, M. Inomata, N. Kuse, N. Awano, M. Tone, K. Takada, Y. Muto, K. Fujimoto, A. Ueda and M. Hayashi, Combination therapy with remdesivir, dexamethasone, and tocilizumab in patients with severe corona virus disease 2019 in clinical practice, Res. Square - preprint posted 16 Oct, 2020; https:\/\/doi.org\/10.21203\/rs.3.rs-91919\/v110.21203\/rs.3.rs-91919\/v1","DOI":"10.21203\/rs.3.rs-91919\/v1"},{"key":"2026051108194149873_j_acph-2022-0030_ref_052","doi-asserted-by":"crossref","unstructured":"52. P. Baghaei, F. Dastan, M. Marjani, A. Moniri, Z. Abtahian, S. Ghadimi, M. Valizadeh, J. Heshmatnia, M. S. Mirenayat, A. Abedini, A. Kiani, A. Eslaminejad, S. M. Hashemian, H. Jamaati, A. Zali, A. A. Velayati and P. Tabarsi, Combination therapy of IFN\u03b21 with lopinavir\u2013ritonavir, increases oxygenation, survival and discharging of severe COVID-19 infected inpatients, Int. Immunopharmacol. 92 (2021) Article ID 107329; https:\/\/doi.org\/10.1016\/j.intimp.2020.10732910.1016\/j.intimp.2020.107329776280133412395","DOI":"10.1016\/j.intimp.2020.107329"},{"key":"2026051108194149873_j_acph-2022-0030_ref_053","doi-asserted-by":"crossref","unstructured":"53. T. Izumo, N. Kuse, N. Awano, M. Tone, K. Sakamoto, K. Takada, Y. Muto, K. Fujimoto, A. Saiki, Y. Ito, H. Matsumoto and M. Inomata, Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19, Respir. Invest. 59(6) (2021) 799\u2013803; https:\/\/doi.org\/10.1016\/j.resinv.2021.07.00410.1016\/j.resinv.2021.07.004835267734413006","DOI":"10.1016\/j.resinv.2021.07.004"},{"key":"2026051108194149873_j_acph-2022-0030_ref_054","doi-asserted-by":"crossref","unstructured":"54. J. V. Fahy and B. F. Dickey, Airway mucus function and dysfunction, N. Engl. J. Med. 363 (2010) 2233\u20132247; https:\/\/doi.org\/10.1056\/NEJMra091006110.1056\/NEJMra0910061404873621121836","DOI":"10.1056\/NEJMra0910061"},{"key":"2026051108194149873_j_acph-2022-0030_ref_055","doi-asserted-by":"crossref","unstructured":"55. A. J. Lier, J. J. Tuan, M. W. Davis, N. Paulson, D. McManus, S. Campbell, D. R. Peaper and J. E. Topal, Case report: Disseminated strongyloidiasis in a patient with COVID-19, Am. J. Trop. Med. Hyg. 103(4) (2020) 1590\u20131592; https:\/\/doi.org\/10.4269\/ajtmh.20-069910.4269\/ajtmh.20-0699754380332830642","DOI":"10.4269\/ajtmh.20-0699"},{"key":"2026051108194149873_j_acph-2022-0030_ref_056","doi-asserted-by":"crossref","unstructured":"56. G. U. Meduri, L. Bridges, M. C. Shih, P. E. Marik, R. C. Siemieniuk and M. Kocak, Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients\u2019 data from four randomized trials and trial-level meta-analysis of the updated literature, Intens. Care Med. 42 (2016) 829\u2013840; https:\/\/doi.org\/10.1007\/s00134-015-4095-410.1007\/s00134-015-4095-426508525","DOI":"10.1007\/s00134-015-4095-4"},{"key":"2026051108194149873_j_acph-2022-0030_ref_057","doi-asserted-by":"crossref","unstructured":"57. A. K. Singh, S. Majumdar, R. Singh and A. Misra, Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician\u2019s perspective, Diabetes Metab. Syndr. Clin. Res. Rev. 14(5) (2020) 971\u2013978; https:\/\/doi.org\/10.1016\/j.dsx.2020.06.05410.1016\/j.dsx.2020.06.054732071332610262","DOI":"10.1016\/j.dsx.2020.06.054"},{"key":"2026051108194149873_j_acph-2022-0030_ref_058","doi-asserted-by":"crossref","unstructured":"58. S. A. Amin, K. Ghosh, S. Gayen and T. Jha, Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors, J. Biomol. Struct. Dyn. 39(13) (2021) 4764\u20134773; https:\/\/doi.org\/10.1080\/07391102.2020.178094610.1080\/07391102.2020.1780946","DOI":"10.1080\/07391102.2020.1780946"},{"key":"2026051108194149873_j_acph-2022-0030_ref_059","doi-asserted-by":"crossref","unstructured":"59. J. J. Condemi, S. Goldstein, C. Kalberg, S. Yancey, A. Emmett and K. Rickard, The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma, Ann. Allergy, Asthma Immunol. 82(4) (1999) 383\u2013389; https:\/\/doi.org\/10.1016\/S1081-1206(10)63288-710.1016\/S1081-1206(10)63288-7","DOI":"10.1016\/S1081-1206(10)63288-7"},{"key":"2026051108194149873_j_acph-2022-0030_ref_060","doi-asserted-by":"crossref","unstructured":"60. A. Woolcock, B. O. Lundback, N. Ringdal and L. A. Jacques, Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids, Am. J. Respir. Crit. Care Med. 153(5) (1996) 1481\u20131488; https:\/\/doi.org\/10.1164\/ajrccm.153.5.863059010.1164\/ajrccm.153.5.86305908630590","DOI":"10.1164\/ajrccm.153.5.8630590"},{"key":"2026051108194149873_j_acph-2022-0030_ref_061","doi-asserted-by":"crossref","unstructured":"61. J. L. Black, B. G. Oliver and M. Roth, Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting \u03b2-agonists, Chest 136(4) (2009) 1095\u20131100; https:\/\/doi.org\/10.1378\/chest.09-035410.1378\/chest.09-035419809050","DOI":"10.1378\/chest.09-0354"},{"key":"2026051108194149873_j_acph-2022-0030_ref_062","doi-asserted-by":"crossref","unstructured":"62. L. Fuso, N. Mores, S. Valente, M. Malerba and P. Montuschi, Long-acting beta-agonists and their association with inhaled corticosteroids in COPD, Curr. Med. Chem. 20(12) (2013) 1477\u20131495; https:\/\/doi.org\/10.2174\/092986731132012000310.2174\/092986731132012000323409722","DOI":"10.2174\/0929867311320120003"},{"key":"2026051108194149873_j_acph-2022-0030_ref_063","doi-asserted-by":"crossref","unstructured":"63. L. J. Nannini, P. Poole, S. J. Milan and A. Kesterton, Combined Corticosteroid and Long-Acting Beta2-Agonist in One Inhaler versus Inhaled Corticosteroids Alone for Chronic Obstructive Pulmonary Disease, in: Cochrane Database Systematic Reviews (Issue 8. Art. No.: CD006826), Cochrane Library 2013, Wiley, Hoboken (NJ, USA), 2014; https:\/\/doi.org\/10.1002\/14651858.CD006826.pub210.1002\/14651858.CD006826.pub2648627423990350","DOI":"10.1002\/14651858.CD006826.pub2"},{"key":"#cr-split#-2026051108194149873_j_acph-2022-0030_ref_064.1","doi-asserted-by":"crossref","unstructured":"64. P. Sinha and B. P. Linas, Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality, Clin. Infect. Dis. 73(11) (2021) 2116-2118","DOI":"10.1093\/cid\/ciab409"},{"key":"#cr-split#-2026051108194149873_j_acph-2022-0030_ref_064.2","doi-asserted-by":"crossref","unstructured":"64. P. Sinha and B. P. Linas, Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality, Clin. Infect. Dis. 73","DOI":"10.1093\/cid\/ciab409"},{"key":"#cr-split#-2026051108194149873_j_acph-2022-0030_ref_064.3","doi-asserted-by":"crossref","unstructured":"(11) (2021) 2116-2118; https:\/\/doi.org\/10.1093\/cid\/ciab409","DOI":"10.1093\/cid\/ciab409"},{"key":"2026051108194149873_j_acph-2022-0030_ref_065","doi-asserted-by":"crossref","unstructured":"65. D. E. Gordon, G. M. Jang, M. Bouhaddou, J. Xu, K. Obernier, K. M. White, M. J. O\u2019Meara, V. V. Rezelj, J. Z. Guo, D. L. Swaney, T. A. Tummino, R. H\u00fcttenhain, R. M. Kaake, A. L. Richards, B. Tutuncuoglu, H. Foussard, J. Batra, K. Haas, M. Modak, M. Kim, P. Haas, B. J. Polacco, H. Braberg, J. M. Fabius, M. Eckhardt, M. Soucheray, M. J. Bennett, M. Cakir, M.. J. McGregor, Q. Li, B. Meyer, F. Roesch, T. Vallet, A. M. Kain, L. Miorin, E. Moreno, Z. C. Naing, Y. Zhou, S. Peng, Y. Shi, Z. Zhang, W. Shen, I. T. Kirby, J. E. Melnyk, J. S. Chorba, K. Lou, S. A. Dai, I. Barrio-Hernandez, D. Memon, C. Hernandez-Armenta, J. Lyu, C. J. Mathy, T. Perica, K. B. Pilla, S. J. Ganesan, D. J. Saltzberg, R. Rakesh, X. Liu, S. B. Rosenthal, L. Calviello, S. Venkataramanan, J. Liboy-Lugo, Y. Lin, X.-P. Huang, Y. F. Liu, S. A. Wankowicz, M. Bohn, M. Safari, F. S. Ugur, C. Koh, N. S. Savar, Q. D. Tran, D. Shengjuler, S. J. Fletcher, M. C. O\u2019Neal, Y. Cai, J. C. Chang, D. J. Broadhurst, S. Klippsten, P. P. Sharp, N. A. Wenzell, D. Kuzuoglu-Ozturk, H.-Y. Wang, R. Trenker, J. M. Young, D. A. Cavero, J. Hiatt, T. L. Roth, U. Rathore, A. Subramanian, J. Noack, M. Hubert, R. M. Stroud, A. D. Frankel, O. S. Rosenberg, K. A. Verba, D. A. Agard, M. Ott, M. Emerman, N. Jura, M. Zastrow, E. Verdin, A. Ashworth, O. Schwartz, C. Enfert, S. Mukherjee, M. Jacobson, H. S. Malik, D. G. Fujimori, T. Ideker, C. S. Craik, S. N. Floor, J. S. Fraser, J. D. Gross, A. Sali, B. L. Roth, D. Ruggero, J. Taunton, T. Kortemme, P. Beltrao, M. Vignuzzi, A. Garc\u00eda-Sastre, K. M. Shokat, B. K. Shoichet and N. J. Krogan, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature 583 (2020) 459\u2013468; https:\/\/doi.org\/10.1038\/s41586-020-2286-910.1038\/s41586-020-2286-9743103032353859","DOI":"10.1038\/s41586-020-2286-9"},{"key":"2026051108194149873_j_acph-2022-0030_ref_066","doi-asserted-by":"crossref","unstructured":"66. Y. Jo, L. Jamieson, I. Edoka, L. Long, S. Silal, J. R. C. Pulliam, H. Moultrie, I. Sanne, G. Meyer-Rath and B. E. Nichols, Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa, Open Forum Inectf. Dis. 8(3) (2021) Article ID ofab040 (8 pages); https:\/\/doi.org\/10.1093\/ofid\/ofab04010.1093\/ofid\/ofab040792862433732750","DOI":"10.1093\/ofid\/ofab040"},{"key":"2026051108194149873_j_acph-2022-0030_ref_067","doi-asserted-by":"crossref","unstructured":"67. S. Nile, A. Nile, J. Qiu, L. Lin, X. Jia and G. Kai, COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons, Cytokine Growth Factor Rev. 53 (2020) 66\u201370; https:\/\/doi.org\/10.1016\/j.cytogfr.2020.05.00210.1016\/j.cytogfr.2020.05.002720466932418715","DOI":"10.1016\/j.cytogfr.2020.05.002"},{"key":"2026051108194149873_j_acph-2022-0030_ref_068","doi-asserted-by":"crossref","unstructured":"68. M. H. Ahmed and A. Hassan. Dexamethasone for the treatment of coronavirus disease (COVID-19): a review, SN Compr. Clin. Med. 2 (2020) 2637\u20132646; https:\/\/doi.org\/10.1007\/s42399-020-00610-810.1007\/s42399-020-00610-8759912133163859","DOI":"10.1007\/s42399-020-00610-8"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/acph-2022-0030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:29:41Z","timestamp":1778488181000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/acph-2022-0030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":72,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,4,13]]},"published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["10.2478\/acph-2022-0030"],"URL":"https:\/\/doi.org\/10.2478\/acph-2022-0030","relation":{},"ISSN":["1846-9558"],"issn-type":[{"value":"1846-9558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,13]]}}}